Radiopharmaceuticals are entering a new phase of strategic attention. As large pharmaceutical companies deepen their investment in radioligand therapies and targeted alpha therapies, the field
Recent developments in radiopharma suggest that clinical progress, infrastructure planning, and operational readiness are becoming more closely linked. Radiopharmaceuticals continue to gain attention as a
Workforce Readiness as a Strategic Determinant of Growth The life sciences industry has entered a phase where scientific acceleration must be matched by operational maturity.
In advanced therapies, outcomes are rarely determined at the point of delivery, they are set much earlier, by decisions teams don’t always recognize. At Orchestra
Execution as a Design Problem in Advanced Therapies Advanced therapies are being shaped by constraints that sit outside the lab. Scientific progress continues, but outcomes
Orchestra Life Sciences’ Year-End Perspectives The life sciences sector entered 2025 with considerable momentum and concluded the year having experienced meaningful scientific, regulatory, and operational
Advanced therapies are rapidly evolving, but talent development has not kept pace. Across the US, companies struggle to hire and retain operators, quality specialists, and
Despite the perceived macroeconomic slowdown, major pharma continues to invest heavily in next-generation gene therapy platforms. Capital is flowing toward programs that show operational growth,
Every industry has its inflection point, for biotech, that moment is unfolding in Philadelphia. Anchored by University City’s innovation corridor, Philadelphia has evolved from an
Author: Zach Lewis, Director, Regulatory and Compliance In today’s race to bring advanced therapies to patients, one hurdle continues to plague the industry: Chemistry, Manufacturing,